

HERCEPTIN HYLECTA Vials 600 mg/5 ml

Version 1.3 Revision Date: 10-28-2022 Date of last issue: 02-25-2020
 Date of first issue: 06-10-2017

SECTION 1. IDENTIFICATION

Product name : HERCEPTIN HYLECTA Vials 600 mg/5 ml
 Product code : RO045-2317/F07
 Common name(s), syno- : HERCEPTIN Vials 600 mg/5 ml
 nym(s) of the substance HERCEPTIN SC (with Hyaluronidase)
Manufacturer or supplier's details
 Company name of supplier : Genentech, Inc.
 Address : 1 DNA Way
 South San Francisco, CA 94080
 USA
 Telephone : 001-(650) 225-1000
 E-mail address : info.sds@roche.com
 Emergency telephone :
 Emergency telephone num- : US Chemtrec phone (800)-424-9300
 ber

Recommended use of the chemical and restrictions on use

Recommended use : Formulated pharmaceutical active substance
 Restrictions on use : For professional users only.

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Not a hazardous substance or mixture.

GHS label elements

Not a hazardous substance or mixture.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Trastuzumab	180288-69-1	12.0
Hyaluronidase	757971-58-7	0.0035
Trehalose (D+)-, 2H2O	6138-23-4	7.95
L-Histidine monohydrochloride monohydrate	5934-29-2	0.37
L-Methionine	63-68-3	0.15

HERCEPTIN HYLECTA Vials 600 mg/5 ml

Version
1.3

Revision Date:
10-28-2022

Date of last issue: 02-25-2020
Date of first issue: 06-10-2017

L-Histidine	71-00-1	0.04
Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.	9005-64-5	0.04
Water	7732-18-5	> 79.0

SECTION 4. FIRST AID MEASURES

- General advice : Do not leave the victim unattended.

- If inhaled : Move to fresh air.
If unconscious, place in recovery position and seek medical advice.
If symptoms persist, call a physician.

- In case of skin contact : If on skin, rinse well with water.

- In case of eye contact : Immediately flush eye(s) with plenty of water.
Remove contact lenses.
Protect unharmed eye.
If eye irritation persists, consult a specialist.

- If swallowed : Keep respiratory tract clear.
Do not give milk or alcoholic beverages.
Never give anything by mouth to an unconscious person.
If symptoms persist, call a physician.
Rinse mouth with water.

- Most important symptoms and effects, both acute and delayed : None known.

- Notes to physician : The first aid procedure should be established in consultation with the doctor responsible for industrial medicine.

SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

- Specific hazards during fire fighting : No information available.

- Hazardous combustion products : In case of fire hazardous decomposition products may be produced such as:
Carbon monoxide
Nitrogen oxides (NOx)
Carbon oxides

- Further information : Standard procedure for chemical fires.
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

- Special protective equipment for fire-fighters : Wear self-contained breathing apparatus for firefighting if necessary.

HERCEPTIN HYLECTA Vials 600 mg/5 ml

Version
1.3

Revision Date:
10-28-2022

Date of last issue: 02-25-2020
Date of first issue: 06-10-2017

SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Avoid exposure
Refer to protective measures listed in sections 7 and 8.
- Environmental precautions : Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Wipe up with absorbent material (e.g. cloth, fleece).
Keep in suitable, closed containers for disposal.

SECTION 7. HANDLING AND STORAGE

- Advice on protection against fire and explosion : Normal measures for preventive fire protection.
- Advice on safe handling : For personal protection see section 8.
Smoking, eating and drinking should be prohibited in the application area.
- Conditions for safe storage : Electrical installations / working materials must comply with the technological safety standards.
- Further information on storage conditions : See label, package insert or internal guidelines
- Materials to avoid : No materials to be especially mentioned.
- Storage temperature : Protected from heat and light
- Further information on storage stability : No decomposition if stored and applied as directed.
- Packaging material : Suitable material: Stainless steel, glass

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Trastuzumab	180288-69-1	IOEL	0.1 mg/m ³	Roche Industrial Hygiene Committee (RIHC)
Hyaluronidase	757971-58-7	IOEL	0.00006 mg/m ³	Roche Industrial Hygiene Committee

HERCEPTIN HYLECTA Vials 600 mg/5 ml

Version
1.3

Revision Date:
10-28-2022

Date of last issue: 02-25-2020
Date of first issue: 06-10-2017

				(RIHC)
--	--	--	--	--------

Engineering measures : No data available

Personal protective equipment

Respiratory protection : No personal respiratory protective equipment normally required.

Hand protection

In case of contact through splashing:
 Material : Nitrile rubber
 Break through time : > 30 min
 Glove thickness : > 0.11 mm

In case of full contact:
 Material : butyl-rubber
 Break through time : > 480 min
 Glove thickness : > 0.4 mm

Remarks : Wear appropriate protective gloves to prevent skin contact. Replace torn or punctured gloves promptly.

Eye protection : Safety glasses

Skin and body protection : Protective suit

Protective measures : Instruction of employees recommended

Hygiene measures : Handle in accordance with good industrial hygiene and safety practice.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : Sterile liquid

Color : colorless, light yellow

Odor : No data available

Odor Threshold : No data available

pH : 5.5

Melting point/range : No data available

Boiling point/boiling range : No data available

Evaporation rate : No data available

Self-ignition : Not applicable

HERCEPTIN HYLECTA Vials 600 mg/5 ml

Version 1.3	Revision Date: 10-28-2022	Date of last issue: 02-25-2020 Date of first issue: 06-10-2017
----------------	------------------------------	---

Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Relative density	:	No data available
Solubility(ies)		
Water solubility	:	completely miscible
Solubility in other solvents	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, dynamic	:	No data available
Viscosity, kinematic	:	No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	No dangerous reaction known under conditions of normal use.
Chemical stability	:	Stable under normal conditions. Proteins are temperature-sensitive; the thermal denaturation has an impact on quality but does not affect Plant and Process Safety; during decomposition no flammable gas, no organic peroxide and no oxidising substances are created Does not contain any antimicrobial preservative; therefore, care must be taken to ensure the sterility of the prepared solution
Possibility of hazardous reactions	:	Stable under recommended storage conditions. No hazards to be specially mentioned.
Conditions to avoid	:	Heat. Exposure to light.
Incompatible materials	:	No data available
Hazardous decomposition products	:	No data available

HERCEPTIN HYLECTA Vials 600 mg/5 ml

Version
1.3

Revision Date:
10-28-2022

Date of last issue: 02-25-2020
Date of first issue: 06-10-2017

SECTION 11. TOXICOLOGICAL INFORMATION

Acute toxicity

Not classified based on available information.

Components:

Trastuzumab:

Acute oral toxicity : Remarks: Not bioavailable by oral administration

Acute toxicity (other routes of administration) : Maximum tolerated dose (Mouse): > 94 mg/kg
Application Route: i.v.

Trehalose (D+)-, 2H₂O:

Acute oral toxicity : LD50 (Rat): 16,000 mg/kg

Hyaluronidase:

Acute oral toxicity : Remarks: Not bioavailable by oral administration

Skin corrosion/irritation

Not classified based on available information.

Components:

Hyaluronidase:

Remarks : This information is not available.

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Hyaluronidase:

Remarks : This information is not available.

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:

Hyaluronidase:

Remarks : May cause sensitization of susceptible persons by skin contact or by inhalation of dust.

Germ cell mutagenicity

Not classified based on available information.

HERCEPTIN HYLECTA Vials 600 mg/5 ml

Version
1.3

Revision Date:
10-28-2022

Date of last issue: 02-25-2020
Date of first issue: 06-10-2017

Carcinogenicity

Not classified based on available information.

IARC No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Not classified based on available information.

Components:

Trastuzumab:

Effects on fetal development : Result: Parenteral administration to pregnant women can cause fetal harm

STOT-single exposure

Not classified based on available information.

Components:

Hyaluronidase:

Assessment : The substance or mixture is not classified as specific target organ toxicant, single exposure.

STOT-repeated exposure

Not classified based on available information.

Components:

Hyaluronidase:

Assessment : The substance or mixture is not classified as specific target organ toxicant, repeated exposure.

Repeated dose toxicity

Components:

Hyaluronidase:

Species : cynomolgus monkey
NOAEL : mg/kg/w, 2
Application Route : s.c.
Exposure time : 39 weeks

Aspiration toxicity

Not classified based on available information.

HERCEPTIN HYLECTA Vials 600 mg/5 ml

 Version
 1.3

 Revision Date:
 10-28-2022

 Date of last issue: 02-25-2020
 Date of first issue: 06-10-2017

Components:
Hyaluronidase:

No data available

Further information
Components:
Trastuzumab:

Remarks : anaphylactic reactions may occur following the intravenous application of proteins; rare cases of hypersensitivity have been described with other monoclonal antibodies

SECTION 12. ECOLOGICAL INFORMATION
Ecotoxicity
Components:
Trehalose (D+)-, 2H₂O:

 Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 100 mg/l
 Exposure time: 96 h
 Test Type: static test

 Toxicity to fish (Chronic toxicity) : NOEC (Danio rerio (zebra fish)): 100 mg/l
 Exposure time: 96 d

Ecotoxicology Assessment

Acute aquatic toxicity : This product has no known ecotoxicological effects.

Chronic aquatic toxicity : This product has no known ecotoxicological effects.

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to the environment : No data available

Hyaluronidase:
Ecotoxicology Assessment

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to the environment : No data available

Persistence and degradability
Components:
Trastuzumab:

 Biodegradability : Result: Readily biodegradable.
 Biodegradation: 65 %

HERCEPTIN HYLECTA Vials 600 mg/5 ml

Version
1.3

Revision Date:
10-28-2022

Date of last issue: 02-25-2020
Date of first issue: 06-10-2017

Exposure time: 14 d
Method: OECD Test Guideline 301F
GLP: yes

Result: Globular proteins are generally well biodegradable

Trehalose (D+)-, 2H2O:

Biodegradability : aerobic
Inoculum: activated sludge, non-adapted
Biochemical oxygen demand
Result: Readily biodegradable.
Biodegradation: 73 %
Method: OECD Test Guideline 301A
Remarks: The 10 day time window criterion is not fulfilled.

aerobic
Inoculum: activated sludge, non-adapted
Dissolved organic carbon (DOC)
Result: Readily biodegradable.
Biodegradation: 98 %
Method: OECD Test Guideline 301A

Hyaluronidase:

Biodegradability : Result: Globular proteins are generally well biodegradable

Bioaccumulative potential

Components:

Trastuzumab:

Partition coefficient: n-octanol/water : Remarks: No data available

Trehalose (D+)-, 2H2O:

Partition coefficient: n-octanol/water : Remarks: No data available

Hyaluronidase:

Partition coefficient: n-octanol/water : Remarks: No data available

Mobility in soil

No data available

Other adverse effects

Product:

Ozone-Depletion Potential : Regulation: 40 CFR Protection of Environment; Part 82 Protection of Stratospheric Ozone - CAA Section 602 Class I Substances
Remarks: This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S.

HERCEPTIN HYLECTA Vials 600 mg/5 ml

Version
1.3

Revision Date:
10-28-2022

Date of last issue: 02-25-2020
Date of first issue: 06-10-2017

Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

Components:

Trastuzumab:

Additional ecological information : Monoclonal antibodies are proteins with highly specific affinity to a certain antigen; therefore, no appreciable ecotoxic potential is to be expected

Hyaluronidase:

Additional ecological information : No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Can be disposed as waste water, when in compliance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
Do not re-use empty containers.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable

Domestic regulation

49 CFR

Not regulated as a dangerous good

Special precautions for user

Remarks : Not dangerous goods in the meaning of ADR/RID, ADN, IMDG-Code, ICAO/IATA-DGR

HERCEPTIN HYLECTA Vials 600 mg/5 ml
Version
1.3Revision Date:
10-28-2022Date of last issue: 02-25-2020
Date of first issue: 06-10-2017

SECTION 15. REGULATORY INFORMATION
CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : No SARA Hazards

SARA 313 : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

Clean Air Act

This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act Section 112 (40 CFR 61).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for Accidental Release Prevention (40 CFR 68.130, Subpart F).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 SOCM Intermediate or Final VOC's (40 CFR 60.489).

Clean Water Act

This product does not contain any Hazardous Substances listed under the U.S. CleanWater Act, Section 311, Table 116.4A.

This product does not contain any Hazardous Chemicals listed under the U.S. CleanWater Act, Section 311, Table 117.3.

This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 307

This product does not contain any priority pollutants related to the U.S. Clean Water Act

US State Regulations**Massachusetts Right To Know**

No components are subject to the Massachusetts Right to Know Act.

Pennsylvania Right To Know

Water	7732-18-5
Trastuzumab	180288-69-1
Trehalose (D+)-, 2H ₂ O	6138-23-4

Maine Chemicals of High Concern

Hyaluronidase	757971-58-7
---------------	-------------

Vermont Chemicals of High Concern

Hyaluronidase	757971-58-7
---------------	-------------

Washington Chemicals of High Concern

Hyaluronidase	757971-58-7
---------------	-------------

The ingredients of this product are reported in the following inventories:

HERCEPTIN HYLECTA Vials 600 mg/5 ml

Version 1.3 Revision Date: 10-28-2022 Date of last issue: 02-25-2020
Date of first issue: 06-10-2017


- AIIC : Not in compliance with the inventory
- DSL : This product contains the following components that are not on the Canadian DSL nor NDSL.
Trastuzumab
L-Histidine monohydrochloride monohydrate
Hyaluronidase
- NZIoC : On the inventory, or in compliance with the inventory
- ENCS : Not in compliance with the inventory
- ISHL : Not in compliance with the inventory
- KECI : Not in compliance with the inventory
- PICCS : Not in compliance with the inventory
- IECSC : Not in compliance with the inventory
- TCSI : Not in compliance with the inventory
- TSCA : Product contains substance(s) not listed on TSCA inventory.
- TECI : Not in compliance with the inventory

TSCA list

No substances are subject to a Significant New Use Rule.

No substances are subject to TSCA 12(b) export notification requirements.

SECTION 16. OTHER INFORMATION

HERCEPTIN HYLECTA Vials 600 mg/5 mlVersion
1.3Revision Date:
10-28-2022Date of last issue: 02-25-2020
Date of first issue: 06-10-2017**NFPA 704:****HMIS® IV:**

HEALTH	/	0
FLAMMABILITY		0
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

AICC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECS - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

HERCEPTIN HYLECTA Vials 600 mg/5 ml

Version 1.3	Revision Date: 10-28-2022	Date of last issue: 02-25-2020 Date of first issue: 06-10-2017
----------------	------------------------------	---

Revision Date : 10-28-2022

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

US / Z8 / 2104